Latest blog postsLearn More

How do you go from doctor to innovator?

A conversation with Gyles Morrison

Dr Gyles Morrison is a Clinical User Experience Specialist and Digital Health Consultant, improving the usability, accessibility and satisfaction people have with healthcare technology. He uses knowledge and experience of behaviour change to improve the way technology is successfully used in healthcare. He has worked with the NHS and a variety of healthcare companies in the UK, South Africa and America on digital healthcare products including Electronic Patient Record systems, remote monitoring tools and digital therapeutics.

Photo by Odette Kármán from Pexels

Your Doctor Needs To Have a Good Team


Carly Flumer

Eric Last

Kimberly Warner

Photo by Cedric Fauntleroy from Pexels

How do we train the doctors we want?


BJ Miller

Eric Last

Carly Flumer

Veronique Mead

Photo by Tima Miroshnichenko from Pexels

Can doctors do something about the wait?


Dr. Eric Last

Carly Flumer

Dana Deighton

Daniel G Garza

Photo by cottonbro from Pexels

The prescription at the end of the consultation


Rick Davis

Carly Flumer

Photo by pina messina on Unsplash

Why your doctor examines you

In the second question in our two-minute question series Dr. Moyez Jiwa, host of the Health Design podcast asks if the clinical examination is a crucial part of the experience when visiting a doctor.

The respondents have all been featured in our podcasts. You an hear the longer conversations here:

Photo by Hush Naidoo on Unsplash

Could the greatest hope for primary care be in a laboratory?

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and damage of the joints affecting about 0.5% of the general population. Early treatment in RA is important as it can prevent disease progression and irreversible damage of the joints. Despite the high diagnostic value of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF), there is a strong demand for novel serological biomarkers to further improve the diagnosis of this abundant disease. During the last decades, several autoantigens have been described in RA including Ra33 (hnRNP A2), fibrinogenfibronectinalpha-enolasetype II collagenimmunoglobulin binding protein (BiP), annexins and viral citrullinated peptide (VCP) derived from Epstein Barr Virus-encoded protein (EBNA-2). More recent discoveries include antibodies to carbamylated antigens (anti-CarP), to peptidyl arginine deiminase type 4 (PAD4), to BRAF (v raf murine sarcoma viral oncogene homologue B1) and to 14 autoantigens identified by phage display technology. This review provides a current overview of novel biomarkers for RA and discusses their future potential to improve the diagnosis of the disease.

Trouw and Mahler

See also my podcast with Sam Mazin

Photo by Jesus Kiteque on Unsplash